BioSpace News Archive

BioStem Technologies Inc. announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024.

SpyGlass Pharma™ announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens based Drug Delivery Platform with bimatoprost at the time of cataract surgery.

Fractyl Health, Inc., a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes, announced the appointment of Adrian Kimber as Chief Commercial Officer.

Pliant Therapeutics, Inc., a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced participation in the following April investor events.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.

Spectral Medical Inc. announced that Anthony Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024.

Bionano Genomics, Inc. announced its participation in the American Association for Cancer Research Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research.

Genetic Technologies Limited is pleased to report the company’s new digital strategy, led by the company’s recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG’s social media platforms.

Quest Diagnostics and Broad Clinical Labs today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company’s in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement of an Investigator-Initiated Trial (IIT).